ENTA
Enanta Pharmaceuticals Inc
12.80$
-2.6%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.3% | 47.7% | 40.6% | 51.2% | 14.1% | 34.8% | 5.8% | -72.1% | -98.4% | -130.2% | -116.5% | -29.5% | |
| 0.7% | 0.4% | 1.9% | 2.1% | 1.2% | 1.6% | 3.0% | 3.4% | 3.5% | 3.0% | 3.5% | 7.8% | |
| 5.6% | 3.6% | 10.6% | 12.7% | 7.7% | 9.4% | 16.0% | 21.6% | 31.3% | 35.6% | 39.6% | 28.4% | |
| -30.3% | 8.6% | 5.4% | 9.9% | 8.0% | 5.0% | 21.6% | 19.9% | 31.6% | – | – | – | |
| -4.7% | -10.5% | 7.0% | 21.4% | -29.9% | 5.6% | 10.5% | -14.1% | 7.9% | 10.1% | 10.5% | 61.1% | |
| 2.2% | 1.5% | 5.4% | 2.4% | 1.4% | 2.6% | 1.2% | 0.8% | 2.5% | 11.4% | 26.5% | 19.7% | |
| 1.0% | -54.8% | -49.5% | -4.4% | -17.1% | -42.2% | 16.2% | 38.1% | 63.7% | -67.6% | 86.1% | 61.8% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.3% | – | – | – | – | – | – | |
| 2.2% | 1.6% | 1.2% | -0.2% | -0.8% | -2.0% | -1.2% | -0.6% | -1.4% | -4.7% | – | – | |
| -0.1% | 0.0% | -0.1% | -0.1% | 0.0% | 0.0% | – | – | 0.0% | 0.0% | -40.6% | – | |
| 2.4% | 1.6% | 3.1% | 1.0% | 2.1% | 1.3% | 7.3% | 3.2% | 23.3% | 250.1% | -40.8% | -40.7% | |
| 45.7% | -5.6% | -5.8% | 47.8% | -0.9% | -6.2% | 29.3% | -30.8% | -11.4% | 52.3% | -71.2% | -8.5% | |
| 40.1% | 46.2% | 35.2% | 48.8% | 12.7% | 32.2% | 4.6% | -72.9% | -100.9% | -141.7% | -143.0% | -49.2% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.